A Change in Promoter Methylation of hMLH1 is a Cause of Acquired Resistance to Platinum-based Chemotherapy in Epithelial Ovarian Cancer

Background: Acquired resistance to platinum-based chemotherapy (Pt-chemo) is a major problem for improving the prognosis for patients with advanced epithelial ovarian cancer (EOC). However, the molecular mechanism of acquired resistance to Pt-chemo is not well understood. Materials and Methods: hMLH...

Full description

Saved in:
Bibliographic Details
Published in:Anticancer research 2007-05, Vol.27 (3B), p.1449-1452
Main Authors: WATANABE, Yoh, UEDA, Haruhiko, ETOH, Tomomaro, KOIKE, Eiji, FUJINAMI, Nahoko, MITSUHASHI, Akiyo, HOSHIAI, Hiroshi
Format: Article
Language:English
Subjects:
Adaptor Proteins, Signal Transducing - genetics
Adult
Aged
Antineoplastic Agents - therapeutic use
Biological and medical sciences
Carcinoma - drug therapy
DNA - analysis
DNA - metabolism
DNA Methylation - drug effects
Drug Resistance, Neoplasm - genetics
Female
Female genital diseases
Gynecology. Andrology. Obstetrics
Humans
Male
Medical sciences
Microsatellite Repeats
Middle Aged
MutL Protein Homolog 1
Nuclear Proteins - genetics
Ovarian Neoplasms - drug therapy
Platinum Compounds - therapeutic use
Promoter Regions, Genetic
Sequence Analysis, DNA
Tumors
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background: Acquired resistance to platinum-based chemotherapy (Pt-chemo) is a major problem for improving the prognosis for patients with advanced epithelial ovarian cancer (EOC). However, the molecular mechanism of acquired resistance to Pt-chemo is not well understood. Materials and Methods: hMLH1 promoter methylation (hMLH1 MET) and hMLH1 protein expression was examined in 36 paired samples of primary and secondary resected tumors by methylation-specific polymerase chain reaction (PCR). Results: No primary tumors exhibited hMLH1 MET, while 56.3% of secondary tumors showed hMLH1 MET. Moreover, no significant correlation was observed between hMLH1 MET and histological subtype, while hMLH1 MET was significantly greater (p
ISSN:0250-7005
1791-7530